Maat Pharma【MAAT】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

8.02

買値

8.00

売値

8.04

出来高

504

7.98 日の範囲 8.02

6.40 52 週間の範囲 9.90

時価総額

93.162M

前日終値

7.98

始値

8.00

時刻

397

8.02

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

2,593

発行済株式数

11,616,199

配当利回り

PER

0.00

1 株当たり利益 (EPS)

歳入

2.23M

純利益

-19.72M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.maatpharma.com

本社

Lyon, Rhone, Fra

設立

Maat Pharma SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker MAAT. The last closing price for Maat Pharma was 7.98 €. Over the last year, Maat Pharma shares have traded in a share price range of 6.40 € to 9.90 €.

Maat Pharma currently has 11,616,199 shares in issue. The market capitalisation of Maat Pharma is 92.70 € million.

CORRIGE ET REMPLACE : MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma organise un webinaire avec des experts le 17 décembre 2024 pour détailler les données et échanger sur les besoins médicaux non satisfaits dans la maladie aiguë du greffon contre...

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) - Register here. Sustained High Response Rates at...

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT033 administered for two months confirmed good safety profile and was well tolerated in patients with ALS. Other study endpoints will be analysed in the upcoming months with full data...

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

Efficacy, safety, and long-term follow-up data from 154 patients in the EAP in Europe further reinforce the excellent clinical profile of MaaT013 in GI-aGvHD. MaaT013 is a safe and effective...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.1	1.26262626263	7.92	8.1	7.88	1636	7.98568633	DE
4	0.3	3.88601036269	7.72	8.36	7.72	4012	8.02856975	DE
12	0.82	11.3888888889	7.2	8.4	6.8	2593	7.89697245	DE
26	0.62	8.37837837838	7.4	8.4	6.8	1893	7.72949525	DE
52	0.84	11.6991643454	7.18	9.9	6.4	1826	7.90706037	DE
156	-5.48	-40.5925925926	13.5	13.55	4.5	1257	8.34595299	DE
260	-5.48	-40.5925925926	13.5	14.4	4.5	1422	9.16940636	DE

MAAT - Frequently Asked Questions (FAQ)

What is the current Maat Pharma share price?

The current share price of Maat Pharma is 8.02 €

How many Maat Pharma shares are in issue?

Maat Pharma has 11,616,199 shares in issue

What is the market cap of Maat Pharma?

The market capitalisation of Maat Pharma is EUR 92.7M

What is the 1 year trading range for Maat Pharma share price?

Maat Pharma has traded in the range of 6.40 € to 9.90 € during the past year

What is the reporting currency for Maat Pharma?

Maat Pharma reports financial results in EUR

What is the latest annual turnover for Maat Pharma?

The latest annual turnover of Maat Pharma is EUR 2.23M

What is the latest annual profit for Maat Pharma?

The latest annual profit of Maat Pharma is EUR -19.72M

What is the registered address of Maat Pharma?

The registered address for Maat Pharma is 70 AVENUE TONY GARNIER, LYON, RHONE, 69007

What is the Maat Pharma website address?

The website address for Maat Pharma is www.maatpharma.com

Which industry sector does Maat Pharma operate in?

Maat Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
MLFXOFinaxo	0.895 € (43.20%)	500
MLWEYWeya	0.0175 € (34.62%)	5.1k
POXELPoxel	0.191 € (33.57%)	4.22M
ALBIOBiosynex	2.50 € (28.73%)	50.71k
SEQUASequana medical NV	3.02 € (23.27%)	1.05M
BNBSTonner Drones	0.0005 € (-50.00%)	524.03k
ALAGOEPango SA	0.127 € (-41.20%)	11.94M
EIFDSTour Eiffel DS	0.0032 € (-38.46%)	33.94k
FINMFinanciere Marjos	0.076 € (-36.13%)	1.4k
ALALOAcheterLouerFR	0.20 € (-33.33%)	90.63k
ATOAtos SE	0.0024 € (-4.00%)	1.53B
BCPBanco Comercial Portugues SA	0.4623 € (0.74%)	43.69M
ALTDTonner Drones	0.0118 € (-7.81%)	27.49M
NEOENNeoen SA	39.74 € (-0.15%)	21.76M
ALVERVergnet	0.002 € (0.00%)	16.8M

銘柄コード

株価

出来高

ATOAtos SE

0.0024 €

(-4.00%)

1.53B

BCPBanco Comercial Portugues SA

0.4623 €

(0.74%)

43.69M

ALTDTonner Drones

0.0118 €

(-7.81%)

27.49M

NEOENNeoen SA

39.74 €

(-0.15%)

21.76M

ALVERVergnet

0.002 €

(0.00%)

16.8M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Maat Pharma SA (MAAT)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Maat Pharma SA について

MAAT 最新ニュース

CORRIGE ET REMPLACE : MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

CORRIGE ET REMPLACE : MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma présentera une mise à jour des données issues de son programme d’accès compassionnel lors du Congrès annuel 2024 de l’ASH démontrant une survie à long terme prolongée chez les patients recevant MaaT013 pour l’aGvH

MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes

MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte

MaaT Pharma publie ses résultats semestriels 2024 et réalise un point sur ses activités

MAAT - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Maat Pharma SA (MAAT) 銘柄情報

Maat Pharma SA (MAAT)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Maat Pharma SA について

MAAT 最新ニュース

MAAT - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手